Biomarkers in asthma, potential for therapeutic intervention

References

• Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;59(6):343–373. doi:10.1183/09031936.00202013.
   Google Scholar
• Custovic A, Siddiqui S, Saglani S. Considering biomarkers in asthma disease severity. J Allergy Clin Immunol. 2022;149(2):480–487. doi:10.1016/j.jaci.2021.11.021.
   PubMed Web of Science ®Google Scholar
• Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, Koth LL, Arron JR, Fahy JV. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med. 2009;180(5):388–395. doi:10.1164/rccm.200903-0392OC.
   PubMed Web of Science ®Google Scholar
• Frøssing L, Silberbrandt A, Von Bülow A, Backer V, Porsbjerg C. The prevalence of subtypes of type 2 inflammation in an unselected population of patients with severe asthma. J Allergy Clin Immunol Pract. 2021;9(3):1267–1275.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Chanez P, Lacoste JY, Barnéon G, Ghavanian N, Enander I, Venge P, Ahlstedt S, Simony-Lafontaine J, Godard P. Eosinophilic inflammation in asthma. N Engl J Med. 1990;323(15):1033–1039. doi:10.1056/NEJM199010113231505.
   PubMed Web of Science ®Google Scholar
• Fitzpatrick AM, Chipps BE, Holguin F, Woodruff PG. T2-"low" asthma: overview and management strategies. J Allergy Clin Immunol Pract. 2020;8(2):452–463. doi:10.1016/j.jaip.2019.11.006.
   PubMed Web of Science ®Google Scholar
• Lapraz JC, Hedayat KM, Pauly P. Endobiogeny: a global approach to systems biology (part 2 of 2). Glob Adv Health Med. 2013;2(2):32–44. doi:10.7453/gahmj.2013.013.
   PubMedGoogle Scholar
• Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov. 2003;2(7):566–580. doi:10.1038/nrd1130.
   PubMed Web of Science ®Google Scholar
• Diamant Z, Vijverberg S, Alving K, Bakirtas A, Bjermer L, Custovic A, Dahlen SE, Gaga M, Gerth van Wijk R, Giacco SD, et al. Toward clinically applicable biomarkers for asthma: an EAACI position paper. Allergy. 2019;74(10):1835–1851. doi:10.1111/all.13806.
   PubMed Web of Science ®Google Scholar
• Agache I, Strasser DS, Klenk A, Agache C, Farine H, Ciobanu C, Groenen PM, Akdis CA. Serum IL-5 and IL-13 consistently serve as the best predictors for the blood eosinophilia phenotype in adult asthmatics. Allergy. 2016;71(8):1192–1202. doi:10.1111/all.12906.
   PubMed Web of Science ®Google Scholar
• Carr TF, Kraft M. Use of biomarkers to identify phenotypes and endotypes of severeasthma. Ann Allergy Asthma Immunol. 2018;121(4):414–420. doi:10.1016/j.anai.2018.07.029.
   PubMed Web of Science ®Google Scholar
• Habib N, Pasha MA, Tang DD. Current understanding of asthma pathogenesis and biomarkers. Cells. 2022;11(17):2764. doi:10.3390/cells11172764.
   PubMed Web of Science ®Google Scholar
• Hur GY, Ye YM, Yang E, Park HS. Serum potential biomarkers according to sputum inflammatory cell profiles in adult asthmatics. Korean J Intern Med. 2020;35(4):988–997. doi:10.3904/kjim.2019.083.
   PubMed Web of Science ®Google Scholar
• Berry M, Morgan A, Shaw DE, Parker D, Green R, Brightling C, Bradding P, Wardlaw AJ, Pavord ID. Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. Thorax. 2007;62(12):1043–1049. doi:10.1136/thx.2006.073429.
   PubMed Web of Science ®Google Scholar
• Gibson PG. Inflammatory phenotypes in adult asthma: clinical applications. Clin Respir J. 2009;3(4):198–206. doi:10.1111/j.1752-699X.2009.00162.x.
   PubMed Web of Science ®Google Scholar
• Pizzichini MM, Popov TA, Efthimiadis A, Hussack P, Evans S, Pizzichini E, Dolovich J, Hargreave FE. Spontaneous and induced sputum to measure indices of airway inflammation in asthma. Am J Respir Crit Care Med. 1996;154(4 Pt 1):866–869. doi:10.1164/ajrccm.154.4.8887576.
   PubMed Web of Science ®Google Scholar
• Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, Wardlaw AJ, Pavord ID. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet. 2002;360(9347):1715–1721.
   PubMed Web of Science ®Google Scholar
• Chiappori A, De Ferrari L, Folli C, Mauri P, Riccio AM, Canonica GW. Biomarkers and severe asthma: a critical appraisal. Clin Mol Allergy. 2015;13(1):20. doi:10.1186/s12948-015-0027-7.
   PubMedGoogle Scholar
• Tran TN, Khatry DB, Ke X, Ward CK, Gossage D. High blood eosinophil count is associated with more frequent asthma attacks in asthma patients. Ann Allergy Asthma Immunol. 2014;113(1):19–24.
   PubMed Web of Science ®Google Scholar
• Horn BR, Robin ED, Theodore J, Van Kessel A. Total eosinophil counts in the management of bronchial asthma. N Engl J Med. 1975;292(22):1152–1155. doi:10.1056/NEJM197505292922204.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207. doi:10.1056/NEJMoa1403290.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–659.
   PubMed Web of Science ®Google Scholar
• Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, Barker P, Sproule S, Ponnarambil S, Goldman M, ZONDA Trial Investigators. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376(25):2448–2458. doi:10.1056/NEJMoa1703501.
   PubMed Web of Science ®Google Scholar
• Lehtimäki L, Shrimanker R, Moran A, Hynes G, Thulborn S, Borg C, Connolly C, Gittins A, Downs T, Russell R. P13 Exhaled nitric oxide and blood eosinophil count in predicting sputum inflammatory type in a heterogeneous airways disease population. Thorax. 2019;74(Suppl 2):A95.
   PubMedGoogle Scholar
• Couillard S, Shrimanker R, Chaudhuri R, Mansur AH, McGarvey LP, Heaney LG, Fowler SJ, Bradding P, Pavord ID, Hinks TSC. Fractional exhaled nitric oxide nonsuppression identifies corticosteroid-resistant type 2 signaling in severe asthma. Am J Respir Crit Care Med. 2021;204(6):731–734. doi:10.1164/rccm.202104-1040LE.
   PubMed Web of Science ®Google Scholar
• Wu LC, Zarrin AA. The production and regulation of IgE by the immune system. Nat Rev Immunol. 2014;14(4):247–259. doi:10.1038/nri3632.
   PubMed Web of Science ®Google Scholar
• Burrows B, Martinez FD, Halonen M, Barbee RA, Cline MG. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med. 1989;320(5):271–277. doi:10.1056/NEJM198902023200502.
   PubMed Web of Science ®Google Scholar
• Vollmer WM, Buist AS, Johnson LR, McCamant LE, Halonen M. Relationship between serum IgE and cross-sectional and longitudinal FEV1 in two cohort studies. Chest. 1986;90(3):416–423. doi:10.1378/chest.90.3.416.
   PubMed Web of Science ®Google Scholar
• Sherrill DL, Lebowitz MD, Halonen M, Barbee RA, Burrows B. Longitudinal evaluation of the association between pulmonary function and total serum IgE. Am J Respir Crit Care Med. 1995;152(1):98–102. doi:10.1164/ajrccm.152.1.7599870.
   PubMed Web of Science ®Google Scholar
• Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108(2):184–190. doi:10.1067/mai.2001.117880.
   PubMed Web of Science ®Google Scholar
• Rath N, Raje N, Rosenwasser L. Immunoglobulin E as a biomarker in asthma. Immunol Allergy Clin North Am. 2018;38(4):587–597. doi:10.1016/j.iac.2018.06.007.
   PubMed Web of Science ®Google Scholar
• Lötvall J, Akdis CA, Bacharier LB, Bjermer L, Casale TB, Custovic A, Lemanske RF, Jr., Wardlaw AJ, Wenzel SE, Greenberger PA. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol. 2011;127(2):355–360. doi:10.1016/j.jaci.2010.11.037.
   PubMed Web of Science ®Google Scholar
• Johansson SG, Hourihane JO, Bousquet J, Bruijnzeel-Koomen C, Dreborg S, Haahtela T, Kowalski ML, Mygind N, Ring J, van Cauwenberge P, et al. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy. 2001;56(9):813–824. doi:10.1034/j.1398-9995.2001.t01-1-00001.x.
   PubMed Web of Science ®Google Scholar
• Zoratti E, Havstad S, Wegienka G, Nicholas C, Bobbitt KR, Woodcroft KJ, Ownby DR, Johnson CC. Differentiating asthma phenotypes in young adults through polyclonal cytokine profiles. Ann Allergy Asthma Immunol. 2014;113(1):25–30. doi:10.1016/j.anai.2014.04.013.
   PubMed Web of Science ®Google Scholar
• Miranda C, Busacker A, Balzar S, Trudeau J, Wenzel SE. Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol. 2004;113(1):101–108. doi:10.1016/j.jaci.2003.10.041.
   PubMed Web of Science ®Google Scholar
• Romanet-Manent S, Charpin D, Magnan A, Lanteaume A, Vervloet D, EGEA Cooperative Group. Allergic vs nonallergic asthma: what makes the difference? Allergy. 2002;57(7):607–613. doi:10.1034/j.1398-9995.2002.23504.x.
   PubMed Web of Science ®Google Scholar
• Lemanske RF, Jr., Busse WW. Asthma: clinical expression and molecular mechanisms. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S95–S102. doi:10.1016/j.jaci.2009.10.047.
   PubMed Web of Science ®Google Scholar
• Castro-Rodríguez JA, Holberg CJ, Wright AL, Martinez FD. A clinical index to define risk of asthma in young children with recurrent wheezing. Am J Respir Crit Care Med. 2000;162(4 Pt 1):1403–1406. doi:10.1164/ajrccm.162.4.9912111.
   PubMed Web of Science ®Google Scholar
• Custovic A, Lazic N, Simpson A. Pediatric asthma and development of atopy. Curr Opin Allergy Clin Immunol. 2013;13(2):173–180. doi:10.1097/ACI.0b013e32835e82b6.
   PubMed Web of Science ®Google Scholar
• Frith J, Fleming L, Bossley C, Ullmann N, Bush A. The complexities of defining atopy in severe childhood asthma. Clin Exp Allergy. 2011;41(7):948–953. doi:10.1111/j.1365-2222.2011.03729.x.
   PubMed Web of Science ®Google Scholar
• Alving K, Weitzberg E, Lundberg JM. Increased amount of nitric oxide in exhaled air of asthmatics. Eur Respir J. 1993;6(9):1368–1370. doi:10.1183/09031936.93.06091368.
   PubMed Web of Science ®Google Scholar
• Chibana K, Trudeau JB, Mustovich AT, Hu H, Zhao J, Balzar S, Chu HW, Wenzel SE. IL-13 induced increases in nitrite levels are primarily driven by increases in inducible nitric oxide synthase as compared with effects on arginases in human primary bronchial epithelial cells. Clin Exp Allergy. 2008;38(6):936–946. doi:10.1111/j.1365-2222.2008.02969.x.
   PubMed Web of Science ®Google Scholar
• Suresh V, Mih JD, George SC. Measurement of IL-13-induced iNOS-derived gas phase nitric oxide in human bronchial epithelial cells. Am J Respir Cell Mol Biol. 2007;37(1):97–104. doi:10.1165/rcmb.2006-0419OC.
   PubMed Web of Science ®Google Scholar
• Pasha MA, Smith TC, Feustel PJ, Jourd’heuil D. Effects of low-dose fluticasone propionate/salmeterol combination therapy on exhaled nitric oxide and nitrite/nitrate in breath condensates from patients with mild persistent asthma. J Asthma. 2013;50(1):64–70.
   PubMed Web of Science ®Google Scholar
• Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, Olin AC, Plummer AL, Taylor DR, American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184(5):602–615. doi:10.1164/rccm.9120-11ST.
   PubMed Web of Science ®Google Scholar
• Bjermer L, Alving K, Diamant Z, Magnussen H, Pavord I, Piacentini G, Price D, Roche N, Sastre J, Thomas M, et al. Current evidence and future research needs for FeNO measurement in respiratory diseases. Respir Med. 2014;108(6):830–841. doi:10.1016/j.rmed.2014.02.005.
   PubMed Web of Science ®Google Scholar
• Petsky HL, Cates CJ, Kew KM, Chang AB. Tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils): a systematic review and meta-analysis. Thorax. 2018;73(12):1110–1119. doi:10.1136/thoraxjnl-2018-211540.
   PubMed Web of Science ®Google Scholar
• Zuiker RG, Boot JD, Calderon C, Piantone A, Petty K, de Kam M, Diamant Z. Sputum induction with hypertonic saline reduces fractional exhaled nitric oxide in chronic smokers and non-smokers. Respir Med. 2010;104(6):917–920. doi:10.1016/j.rmed.2010.02.006.
   PubMed Web of Science ®Google Scholar
• Boot JD, de Kam ML, Mascelli MA, Miller B, van Wijk RG, de Groot H, Cohen AF, Diamant Z. Nasal nitric oxide: longitudinal reproducibility and the effects of a nasal allergen challenge in patients with allergic rhinitis. Allergy. 2007;62(4):378–384. doi:10.1111/j.1398-9995.2007.01328.x.
   PubMed Web of Science ®Google Scholar
• Kostikas K, Minas M, Papaioannou AI, Papiris S, Dweik RA. Exhaled nitric oxide in asthma in adults: the end is the beginning? Curr Med Chem. 2011;18(10):1423–1431. doi:10.2174/092986711795328436.
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Mansur AH, Brightling CE. Clinical utility of fractional exhaled nitric oxide in severe asthma management. Eur Respir J. 2020;55(3):1901633. doi:10.1183/13993003.01633-2019.
   PubMed Web of Science ®Google Scholar
• Kharitonov SA, Yates DH, Barnes PJ. Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients. Am J Respir Crit Care Med. 1996;153(1):454–457. doi:10.1164/ajrccm.153.1.8542158.
   PubMed Web of Science ®Google Scholar
• Woodruff PG, Boushey HA, Dolganov GM, Barker CS, Yang YH, Donnelly S, Ellwanger A, Sidhu SS, Dao-Pick TP, Pantoja C, et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci U S A. 2007;104(40):15858–15863. doi:10.1073/pnas.0707413104.
   PubMed Web of Science ®Google Scholar
• Yuyama N, Davies DE, Akaiwa M, Matsui K, Hamasaki Y, Suminami Y, Yoshida NL, Maeda M, Pandit A, Lordan JL, et al. Analysis of novel disease-related genes in bronchial asthma. Cytokine. 2002;19(6):287–296. doi:10.1006/cyto.2002.1972.
   PubMed Web of Science ®Google Scholar
• Takayama G, Arima K, Kanaji T, Toda S, Tanaka H, Shoji S, McKenzie AN, Nagai H, Hotokebuchi T, Izuhara K. Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol. 2006;118(1):98–104. doi:10.1016/j.jaci.2006.02.046.
   PubMed Web of Science ®Google Scholar
• Jia G, Erickson RW, Choy DF, Mosesova S, Wu LC, Solberg OD, Shikotra A, Carter R, Audusseau S, Hamid Q, et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol. 2012;130(3):647–654.e10. doi:10.1016/j.jaci.2012.06.025.
   PubMed Web of Science ®Google Scholar
• Fowler SJ, Dempsey OJ, Sims EJ, Lipworth BJ. Screening for bronchial hyperresponsiveness using methacholine and adenosine monophosphate. Relationship to asthma severity and beta(2)-receptor genotype. Am J Respir Crit Care Med. 2000;162(4 Pt 1):1318–1322. doi:10.1164/ajrccm.162.4.9912103.
   PubMed Web of Science ®Google Scholar
• Sont JK, Willems LN, Bel EH, van Krieken JH, Vandenbroucke JP, Sterk PJ. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med. 1999;159(4 Pt 1):1043–1051. doi:10.1164/ajrccm.159.4.9806052.
   PubMed Web of Science ®Google Scholar
• Cockcroft D, Davis B. Direct and indirect challenges in the clinical assessment of asthma. Ann Allergy Asthma Immunol. 2009;103(5):363–369. quiz 369-72, 400. doi:10.1016/S1081-1206(10)60353-5.
   PubMed Web of Science ®Google Scholar
• Nair P, Martin JG, Cockcroft DC, Dolovich M, Lemiere C, Boulet LP, O'Byrne PM. Airway hyperresponsiveness in asthma: measurement and clinical relevance. J Allergy Clin Immunol Pract. 2017;5(3):649–659.e2. doi:10.1016/j.jaip.2016.11.030.
   PubMed Web of Science ®Google Scholar
• Payne DN, Adcock IM, Wilson NM, Oates T, Scallan M, Bush A. Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in children with difficult asthma, after treatment with oral prednisolone. Am J Respir Crit Care Med. 2001;164(8 Pt 1):1376–1381. doi:10.1164/ajrccm.164.8.2101145.
   PubMed Web of Science ®Google Scholar
• Salome CM, Roberts AM, Brown NJ, Dermand J, Marks GB, Woolcock AJ. Exhaled nitric oxide measurements in a population sample of young adults. Am J Respir Crit Care Med. 1999;159(3):911–916. doi:10.1164/ajrccm.159.3.9802108.
   PubMedGoogle Scholar
• Downie SR, Salome CM, Verbanck S, Thompson B, Berend N, King GG. Ventilation heterogeneity is a major determinant of airway hyperresponsiveness in asthma, independent of airway inflammation. Thorax. 2007;62(8):684–689. doi:10.1136/thx.2006.069682.
   PubMed Web of Science ®Google Scholar
• Sverrild A, Porsbjerg C, Thomsen SF, Backer V. Airway hyperresponsiveness to mannitol and methacholine and exhaled nitric oxide: a random-sample population study. J Allergy Clin Immunol. 2010;126(5):952–958. doi:10.1016/j.jaci.2010.08.028.
   PubMed Web of Science ®Google Scholar
• Anderson SD, Charlton B, Weiler JM, Nichols S, Spector SL, Pearlman DS, A305 Study Group Comparison of mannitol and methacholine to predict exercise-induced bronchoconstriction and a clinical diagnosis of asthma. Respir Res. 2009;10(1):4. doi:10.1186/1465-9921-10-4.
   PubMed Web of Science ®Google Scholar
• Kim MH, Song WJ, Kim TW, Jin HJ, Sin YS, Ye YM, Kim SH, Park HW, Lee BJ, Park HS, et al. Diagnostic properties of the methacholine and mannitol bronchial challenge tests: a comparison study. Respirology. 2014;19(6):852–856. doi:10.1111/resp.12334.
   PubMed Web of Science ®Google Scholar
• Chapman DG, Irvin CG. Mechanisms of airway hyper-responsiveness in asthma: the past, present and yet to come. Clin Exp Allergy. 2015;45(4):706–719. doi:10.1111/cea.12506.
   PubMed Web of Science ®Google Scholar
• Hargreave FE, Nair P. The definition and diagnosis of asthma. Clin Exp Allergy. 2009;39(11):1652–1658. doi:10.1111/j.1365-2222.2009.03321.x.
   PubMed Web of Science ®Google Scholar
• Bradding P, Arthur G. Mast cells in asthma–state of the art. Clin Experimental Allergy. 2016;46(2):194–263. doi:10.1111/cea.12675.
   PubMed Web of Science ®Google Scholar
• Wilson SJ, Ward JA, Sousa AR, Corfield J, Bansal AT, De Meulder B, Lefaudeux D, Auffray C, Loza MJ, Baribaud F, et al. Severe asthma exists despite suppressed tissue inflammation: findings of the U-BIOPRED study. Eur Respir J. 2016;48(5):1307–1319. doi:10.1183/13993003.01129-2016.
   PubMed Web of Science ®Google Scholar
• Siddiqui S, Mistry V, Doe C, Roach K, Morgan A, Wardlaw A, Pavord I, Bradding P, Brightling C. Airway hyperresponsiveness is dissociated from airway wall structural remodeling. J Allergy Clin Immunol. 2008;122(2):335–341.e3. doi:10.1016/j.jaci.2008.05.020.
   PubMed Web of Science ®Google Scholar
• Da Silva CA, Reber L, Frossard N. Stem cell factor expression, mast cells and inflammation in asthma. Fundam Clin Pharmacol. 2006;20(1):21–39. doi:10.1111/j.1472-8206.2005.00390.x.
   PubMed Web of Science ®Google Scholar
• Makowska JS, Cieslak M, Kowalski ML. Stem cell factor and its soluble receptor (c-kit) in serum of asthmatic patients- correlation with disease severity. BMC Pulm Med. 2009;9(1):27. doi:10.1186/1471-2466-9-27.
   PubMedGoogle Scholar
• Hallgren J, Pejler G. Biology of mast cell tryptase. An inflammatory mediator. FEBS J. 2006;273(9):1871–1895. doi:10.1111/j.1742-4658.2006.05211.x.
   PubMed Web of Science ®Google Scholar
• Schwartz LB, Lewis RA, Austen KF. Tryptase from human pulmonary mast cells. Purification and characterization. J Biol Chem. 1981;256(22):11939–11943.
   PubMed Web of Science ®Google Scholar
• Jogie-Brahim S, Min HK, Fukuoka Y, Xia HZ, Schwartz LB. Expression of alpha-tryptase and beta-tryptase by human basophils. J Allergy Clin Immunol. 2004;113(6):1086–1092. doi:10.1016/j.jaci.2004.02.032.
   PubMed Web of Science ®Google Scholar
• Kraft M, Martin RJ, Lazarus SC, Fahy JV, Boushey HA, Lemanske RF, Jr., Szefler SJ, Asthma Clinical Research Network. Airway tissue mast cells in persistent asthma: predictor of treatment failure when patients discontinue inhaled corticosteroids. Chest. 2003;124(1):42–50. doi:10.1378/chest.124.1.42.
   PubMed Web of Science ®Google Scholar
• Cahill KN, Katz HR, Cui J, Lai J, Kazani S, Crosby-Thompson A, Garofalo D, Castro M, Jarjour N, DiMango E, et al. KIT inhibition by imatinib in patients with severe refractory asthma. N Engl J Med. 2017;376(20):1911–1920. doi:10.1056/NEJMoa1613125.
   PubMed Web of Science ®Google Scholar
• Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID. Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med. 2002;346(22):1699–1705. doi:10.1056/NEJMoa012705.
   PubMed Web of Science ®Google Scholar
• Kaur D, Saunders R, Hollins F, Woodman L, Doe C, Siddiqui S, Bradding P, Brightling C. Mast cell fibroblastoid differentiation mediated by airway smooth muscle in asthma. J Immunol. 2010;185(10):6105–6114. doi:10.4049/jimmunol.1000638.
   PubMed Web of Science ®Google Scholar
• Cui Y, Dahlin JS, Feinstein R, Bankova LG, Xing W, Shin K, Gurish MF, Hallgren J. Mouse mast cell protease-6 and MHC are involved in the development of experimental asthma. J Immunol. 2014;193(10):4783–4789. doi:10.4049/jimmunol.1302947.
   PubMed Web of Science ®Google Scholar
• Maun HR, Jackman JK, Choy DF, Loyet KM, Staton TL, Jia G, Dressen A, Hackney JA, Bremer M, Walters BT, et al. An allosteric anti-tryptase antibody for the treatment of mast cell-mediated severe asthma. Cell. 2019;179(2):417–431.e19. doi:10.1016/j.cell.2019.09.009.
   PubMed Web of Science ®Google Scholar
• Sze E, Bhalla A, Nair P. Mechanisms and therapeutic strategies for non-T2 asthma. Allergy. 2020;75(2):311–325. doi:10.1111/all.13985.
   PubMed Web of Science ®Google Scholar
• Tliba O, Panettieri RA.Jr., Paucigranulocytic asthma: uncoupling of airway obstruction from inflammation. J Allergy Clin Immunol. 2019;143(4):1287–1294. doi:10.1016/j.jaci.2018.06.008.
   PubMed Web of Science ®Google Scholar
• Breiteneder H, Peng YQ, Agache I, Diamant Z, Eiwegger T, Fokkens WJ, Traidl-Hoffmann C, Nadeau K, O'Hehir RE, O'Mahony L, et al. Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma. Allergy. 2020;75(12):3039–3068. doi:10.1111/all.14582.
   PubMed Web of Science ®Google Scholar
• Alam R, Good J, Rollins D, Verma M, Chu H, Pham TH, Martin RJ. Airway and serum biochemical correlates of refractory neutrophilic asthma. J Allergy Clin Immunol. 2017;140(4):1004–1014.e13. doi:10.1016/j.jaci.2016.12.963.
   PubMed Web of Science ®Google Scholar
• McGrath KW, Icitovic N, Boushey HA, Lazarus SC, Sutherland ER, Chinchilli VM, Fahy JV, Asthma Clinical Research Network of the National Heart, Lung, and Blood Institute. A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. Am J Respir Crit Care Med. 2012;185(6):612–619. doi:10.1164/rccm.201109-1640OC.
   PubMed Web of Science ®Google Scholar
• Simpson JL, Powell H, Boyle MJ, Scott RJ, Gibson PG. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med. 2008;177(2):148–155. doi:10.1164/rccm.200707-1134OC.
   PubMed Web of Science ®Google Scholar
• Green RH, Brightling CE, Woltmann G, Parker D, Wardlaw AJ, Pavord ID. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax. 2002;57(10):875–879. doi:10.1136/thorax.57.10.875.
   PubMed Web of Science ®Google Scholar
• Schleich FN, Chevremont A, Paulus V, Henket M, Manise M, Seidel L, Louis R. Importance of concomitant local and systemic eosinophilia in uncontrolled asthma. Eur Respir J. 2014;44(1):97–108. doi:10.1183/09031936.00201813.
   PubMed Web of Science ®Google Scholar
• Simpson JL, Scott R, Boyle MJ, Gibson PG. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology. 2006;11(1):54–61. doi:10.1111/j.1440-1843.2006.00784.x.
   PubMed Web of Science ®Google Scholar
• Moore WC, Hastie AT, Li X, Li H, Busse WW, Jarjour NN, Wenzel SE, Peters SP, Meyers DA, Bleecker ER, National Heart, Lung, and Blood Institute’s Severe Asthma Research Program. Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis. J Allergy Clin Immunol. 2014;133(6):1557–1563.e5. doi:10.1016/j.jaci.2013.10.011.
   PubMed Web of Science ®Google Scholar
• Peters MC, McGrath KW, Hawkins GA, Hastie AT, Levy BD, Israel E, Phillips BR, Mauger DT, Comhair SA, Erzurum SC, et al. Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross-sectional analysis of two cohorts. Lancet Respir Med. 2016;4(7):574–584. doi:10.1016/S2213-2600(16)30048-0.
   PubMed Web of Science ®Google Scholar
• Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest. 2011;121(6):2111–2117. doi:10.1172/JCI57132.
   PubMed Web of Science ®Google Scholar
• Yokoyama A, Kohno N, Fujino S, Hamada H, Inoue Y, Fujioka S, Ishida S, Hiwada K. Circulating interleukin-6 levels in patients with bronchial asthma. Am J Respir Crit Care Med. 1995;151(5):1354–1358. doi:10.1164/ajrccm.151.5.7735584.
   PubMed Web of Science ®Google Scholar
• Wang YH, Voo KS, Liu B, Chen CY, Uygungil B, Spoede W, Bernstein JA, Huston DP, Liu YJ. A novel subset of CD4(+) T(H)2 memory/effector cells that produce inflammatory IL-17 cytokine and promote the exacerbation of chronic allergic asthma. J Exp Med. 2010;207(11):2479–2491. doi:10.1084/jem.20101376.
   PubMed Web of Science ®Google Scholar
• Molet S, Hamid Q, Davoine F, Nutku E, Taha R, Pagé N, Olivenstein R, Elias J, Chakir J. IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J Allergy Clin Immunol. 2001;108(3):430–438. doi:10.1067/mai.2001.117929.
   PubMed Web of Science ®Google Scholar
• Irvin C, Zafar I, Good J, Rollins D, Christianson C, Gorska MM, Martin RJ, Alam R. Increased frequency of dual-positive TH2/TH17 cells in bronchoalveolar lavage fluid characterizes a population of patients with severe asthma. J Allergy Clin Immunol. 2014;134(5):1175–1186.e7. doi:10.1016/j.jaci.2014.05.038.
   PubMed Web of Science ®Google Scholar
• Doe C, Bafadhel M, Siddiqui S, Desai D, Mistry V, Rugman P, McCormick M, Woods J, May R, Sleeman MA, et al. Expression of the T helper 17-associated cytokines IL-17A and IL-17F in asthma and COPD. Chest. 2010;138(5):1140–1147. doi:10.1378/chest.09-3058.
   PubMed Web of Science ®Google Scholar
• Chien JW, Lin CY, Yang KD, Lin CH, Kao JK, Tsai YG. Increased IL-17A secreting CD4+ T cells, serum IL-17 levels and exhaled nitric oxide are correlated with childhood asthma severity. Clin Exp Allergy. 2013;43(9):1018–1026. doi:10.1111/cea.12119.
   PubMed Web of Science ®Google Scholar
• Bullens DM, Truyen E, Coteur L, Dilissen E, Hellings PW, Dupont LJ, Ceuppens JL. IL-17 mRNA in sputum of asthmatic patients: linking T cell driven inflammation and granulocytic influx? Respir Res. 2006;7(1):135. doi:10.1186/1465-9921-7-135.
   PubMed Web of Science ®Google Scholar
• Al-Ramli W, Préfontaine D, Chouiali F, Martin JG, Olivenstein R, Lemière C, Hamid Q. T(H)17-associated cytokines (IL-17A and IL-17F) in severe asthma. J Allergy Clin Immunol. 2009;123(5):1185–1187. doi:10.1016/j.jaci.2009.02.024.
   PubMed Web of Science ®Google Scholar
• Brandt EB, Kovacic MB, Lee GB, Gibson AM, Acciani TH, Le Cras TD, Ryan PH, Budelsky AL, Khurana Hershey GK. Diesel exhaust particle induction of IL-17A contributes to severe asthma. J Allergy Clin Immunol. 2013;132(5):1194–1204.e2. doi:10.1016/j.jaci.2013.06.048.
   PubMed Web of Science ®Google Scholar
• Kim HY, Lee HJ, Chang YJ, Pichavant M, Shore SA, Fitzgerald KA, Iwakura Y, Israel E, Bolger K, Faul J, et al. Interleukin-17-producing innate lymphoid cells and the NLRP3 inflammasome facilitate obesity-associated airway hyperreactivity. Nat Med. 2014;20(1):54–61. doi:10.1038/nm.3423.
   PubMed Web of Science ®Google Scholar
• Agache I, Ciobanu C, Agache C, Anghel M. Increased serum IL-17 is an independent risk factor for severe asthma. Respir Med. 2010;104(8):1131–1137. doi:10.1016/j.rmed.2010.02.018.
   PubMed Web of Science ®Google Scholar
• Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012;11(10):763–776. doi:10.1038/nrd3794.
   PubMed Web of Science ®Google Scholar
• McKinley L, Alcorn JF, Peterson A, Dupont RB, Kapadia S, Logar A, Henry A, Irvin CG, Piganelli JD, Ray A, et al. TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice. J Immunol. 2008;181(6):4089–4097. doi:10.4049/jimmunol.181.6.4089.
   PubMed Web of Science ®Google Scholar
• Pace-Asciak CR, Martin JM, Corey EJ. Hepoxilins, potential endogenous mediators of insulin release. Prog Lipid Res. 1986;25(1-4):625–628. doi:10.1016/0163-7827(86)90127-x.
   PubMedGoogle Scholar
• Willis CR, Siegel L, Leith A, Mohn D, Escobar S, Wannberg S, Misura K, Rickel E, Rottman JB, Comeau MR, et al. IL-17RA signaling in airway inflammation and bronchial hyperreactivity in allergic asthma. Am J Respir Cell Mol Biol. 2015;53(6):810–821. doi:10.1165/rcmb.2015-0038OC.
   PubMed Web of Science ®Google Scholar
• Busse WW, Holgate S, Kerwin E, Chon Y, Feng J, Lin J, Lin SL. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med. 2013;188(11):1294–1302. doi:10.1164/rccm.201212-2318OC.
   PubMed Web of Science ®Google Scholar
• Sampath D, Castro M, Look DC, Holtzman MJ. Constitutive activation of an epithelial signal transducer and activator of transcription (STAT) pathway in asthma. J Clin Invest. 1999;103(9):1353–1361. doi:10.1172/JCI6130.
   PubMed Web of Science ®Google Scholar
• Raundhal M, Morse C, Khare A, Oriss TB, Milosevic J, Trudeau J, Huff R, Pilewski J, Holguin F, Kolls J, et al. High IFN-γ and low SLPI mark severe asthma in mice and humans. J Clin Invest. 2015;125(8):3037–3050. doi:10.1172/JCI80911.
   PubMed Web of Science ®Google Scholar
• Oriss TB, Raundhal M, Morse C, Huff RE, Das S, Hannum R, Gauthier MC, Scholl KL, Chakraborty K, Nouraie SM, et al. IRF5 distinguishes severe asthma in humans and drives Th1 phenotype and airway hyperreactivity in mice. JCI Insight. 2017;2(10):e91019. doi:10.1172/jci.insight.91019.
   PubMed Web of Science ®Google Scholar
• Gauthier M, Chakraborty K, Oriss TB, Raundhal M, Das S, Chen J, Huff R, Sinha A, Fajt M, Ray P, et al. Severe asthma in humans and mouse model suggests a CXCL10 signature underlies corticosteroid-resistant Th1 bias. JCI Insight. 2017;2(13):e94580. doi:10.1172/jci.insight.94580.
   PubMed Web of Science ®Google Scholar
• Bhakta NR, Christenson SA, Nerella S, Solberg OD, Nguyen CP, Choy DF, Jung KL, Garudadri S, Bonser LR, Pollack JL, et al. IFN-stimulated gene expression, type 2 inflammation, and endoplasmic reticulum stress in asthma. Am J Respir Crit Care Med. 2018;197(3):313–324. doi:10.1164/rccm.201706-1070OC.
   PubMed Web of Science ®Google Scholar
• Wark PA, Johnston SL, Bucchieri F, Powell R, Puddicombe S, Laza-Stanca V, Holgate ST, Davies DE. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med. 2005;201(6):937–947. doi:10.1084/jem.20041901.
   PubMed Web of Science ®Google Scholar
• Edwards MR, Regamey N, Vareille M, Kieninger E, Gupta A, Shoemark A, Saglani S, Sykes A, Macintyre J, Davies J, et al. Impaired innate interferon induction in severe therapy resistant atopic asthmatic children. Mucosal Immunol. 2013;6(4):797–806. doi:10.1038/mi.2012.118.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Wenzel S, Rosén K, Hsieh HJ, Mosesova S, Choy DF, Lal P, Arron JR, Harris JM, Busse W. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187(8):804–811. doi:10.1164/rccm.201208-1414OC.
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Miyata M, Ohba T, Ando T, Hatsushika K, Suenaga F, Shimokawa N, Ohnuma Y, Katoh R, Ogawa H, et al. Cigarette smoke extract induces thymic stromal lymphopoietin expression, leading to T(H)2-type immune responses and airway inflammation. J Allergy Clin Immunol. 2008;122(6):1208–1214.
   PubMed Web of Science ®Google Scholar
• Bleck B, Tse DB, Curotto de Lafaille MA, Zhang F, Reibman J. Diesel exhaust particle-exposed human bronchial epithelial cells induce dendritic cell maturation and polarization via thymic stromal lymphopoietin. J Clin Immunol. 2008;28(2):147–156. doi:10.1007/s10875-007-9149-0.
   PubMed Web of Science ®Google Scholar
• Kouzaki H, O'Grady SM, Lawrence CB, Kita H. Proteases induce production of thymic stromal lymphopoietin by airway epithelial cells through protease-activated receptor-2. J Immunol. 2009;183(2):1427–1434. doi:10.4049/jimmunol.0900904.
   PubMed Web of Science ®Google Scholar
• Shikotra A, Choy DF, Ohri CM, Doran E, Butler C, Hargadon B, Shelley M, Abbas AR, Austin CD, Jackman J, et al. Increased expression of immunoreactive thymic stromal lymphopoietin in patients with severe asthma. J Allergy Clin Immunol. 2012;129(1):104–111.e1-9. doi:10.1016/j.jaci.2011.08.031.
   PubMed Web of Science ®Google Scholar
• Liu S, Verma M, Michalec L, Liu W, Sripada A, Rollins D, Good J, Ito Y, Chu H, Gorska MM, et al. Steroid resistance of airway type 2 innate lymphoid cells from patients with severe asthma: the role of thymic stromal lymphopoietin. J Allergy Clin Immunol. 2018;141(1):257–268.e6. doi:10.1016/j.jaci.2017.03.032.
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, Sehmi R, Ambrose CS, Griffiths JM. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777–792. doi:10.1080/14728222.2020.1783242.
   PubMed Web of Science ®Google Scholar
• Allakhverdi Z, Comeau MR, Jessup HK, Yoon BR, Brewer A, Chartier S, Paquette N, Ziegler SF, Sarfati M, Delespesse G. Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells. J Exp Med. 2007;204(2):253–258. doi:10.1084/jem.20062211.
   PubMed Web of Science ®Google Scholar
• Soumelis V, Reche PA, Kanzler H, Yuan W, Edward G, Homey B, Gilliet M, Ho S, Antonenko S, Lauerma A, et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol. 2002;3(7):673–680. doi:10.1038/ni805.
   PubMed Web of Science ®Google Scholar
• Kitajima M, Lee HC, Nakayama T, Ziegler SF. TSLP enhances the function of helper type 2 cells. Eur J Immunol. 2011;41(7):1862–1871. doi:10.1002/eji.201041195.
   PubMed Web of Science ®Google Scholar
• Liang Y, Yu B, Chen J, Wu H, Xu Y, Yang B, Lu Q. Thymic stromal lymphopoietin epigenetically upregulates Fc receptor γ subunit-related receptors on antigen-presenting cells and induces T(H)2/T(H)17 polarization through dectin-2. J Allergy Clin Immunol. 2019;144(4):1025–1035.e7. doi:10.1016/j.jaci.2019.06.011.
   PubMed Web of Science ®Google Scholar
• Tanaka J, Watanabe N, Kido M, Saga K, Akamatsu T, Nishio A, Chiba T. Human TSLP and TLR3 ligands promote differentiation of Th17 cells with a central memory phenotype under Th2-polarizing conditions. Clin Exp Allergy. 2009;39(1):89–100. doi:10.1111/j.1365-2222.2008.03151.x.
   PubMed Web of Science ®Google Scholar
• West EE, Spolski R, Kazemian M, Yu ZX, Kemper C, Leonard WJ. A TSLP-complement axis mediates neutrophil killing of methicillin-resistant Staphylococcus aureus. Sci Immunol. 2016;1(5):aaf8471. doi:10.1126/sciimmunol.aaf8471.
   Web of Science ®Google Scholar
• Allakhverdi Z, Comeau MR, Jessup HK, Delespesse G. Thymic stromal lymphopoietin as a mediator of crosstalk between bronchial smooth muscles and mast cells. J Allergy Clin Immunol. 2009;123(4):958–960.e2. doi:10.1016/j.jaci.2009.01.059.
   PubMed Web of Science ®Google Scholar
• Porsbjerg CM, Sverrild A, Lloyd CM, Menzies-Gow AN, Bel EH. Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics. Eur Respir J. 2020;56(5):2000260. doi:10.1183/13993003.00260-2020.
   PubMed Web of Science ®Google Scholar
• Corren J, Garcia Gil E, Parnes J, Pham T-H, Griffiths J. Tezepelumab treatment effect on annualized rate of exacerbations by baseline biomarkers in uncontrolled severe asthma patients: phase 2b PATHWAY study. In B15. Immunotherapy for lung Disease. 2019. Dallas, TX: American Thoracic Society. doi:10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A2621.
   Google Scholar
• Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med. 2000;161(5):1720–1745. doi:10.1164/ajrccm.161.5.9903102.
   PubMed Web of Science ®Google Scholar
• O’Byrne P, Bateman E, Bousquet J, Clark T, Ohta K, Paggiaro P. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Updated 2006, 2012.
   Google Scholar
• Bianco A, Contoli M, Di Marco F, Saverio Mennini F, Papi A, participants of the regional meetings. As-needed anti-inflammatory reliever therapy for asthma management: evidence and practical considerations. Clin Exp Allergy. 2021;51(7):873–882. doi:10.1111/cea.13795.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, Pedersen SE, GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med. 2004;170(8):836–844. doi:10.1164/rccm.200401-033OC.
   PubMed Web of Science ®Google Scholar
• Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60(3):309–316. doi:10.1111/j.1398-9995.2004.00772.x.
   PubMed Web of Science ®Google Scholar
• Szefler SJ, Martin RJ, King TS, Boushey HA, Cherniack RM, Chinchilli VM, Craig TJ, Dolovich M, Drazen JM, Fagan JK, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol. 2002;109(3):410–418. doi:10.1067/mai.2002.122635.
   PubMed Web of Science ®Google Scholar
• Szefler SJ, Martin RJ. Lessons learned from variation in response to therapy in clinical trials. J Allergy Clin Immunol. 2010;125(2):285–292. quiz 293-4. doi:10.1016/j.jaci.2009.10.026.
   PubMed Web of Science ®Google Scholar
• Bossley CJ, Fleming L, Ullmann N, Gupta A, Adams A, Nagakumar P, Bush A, Saglani S. Assessment of corticosteroid response in pediatric patients with severe asthma by using a multidomain approach. J Allergy Clin Immunol. 2016;138(2):413–420.e6. doi:10.1016/j.jaci.2015.12.1347.
   PubMed Web of Science ®Google Scholar
• Fleming L, Koo M, Bossley CJ, Nagakumar P, Bush A, Saglani S. The utility of a multidomain assessment of steroid response for predicting clinical response to omalizumab. J Allergy Clin Immunol. 2016;138(1):292–294. doi:10.1016/j.jaci.2015.12.1317.
   PubMed Web of Science ®Google Scholar
• Novartis U. Genentech. Omalizumab (Xolair) label. 2010. Morris Plains, NJ: Genentech and Novartis Pharma.
   Google Scholar
• Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P, Fox H. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest. 2004;125(4):1378–1386. doi:10.1378/chest.125.4.1378.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Rabe K, Humbert M, Chung KF, Berger W, Fox H, Ayre G, Chen H, Thomas K, Blogg M, et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med. 2007;101(7):1483–1492.
   PubMed Web of Science ®Google Scholar
• Wahn U, Martin C, Freeman P, Blogg M, Jimenez P. Relationship between pretreatment specific IgE and the response to omalizumab therapy. Allergy. 2009;64(12):1780–1787. doi:10.1111/j.1398-9995.2009.02119.x.
   PubMed Web of Science ®Google Scholar
• Korn S, Haasler I, Fliedner F, Becher G, Strohner P, Staatz A, Taube C, Buhl R. Monitoring free serum IgE in severe asthma patients treated with omalizumab. Respir Med. 2012;106(11):1494–1500. doi:10.1016/j.rmed.2012.07.010.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, Rosen KE, Eisner MD, Wong DA, Busse W. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011;154(9):573–582. doi:10.7326/0003-4819-154-9-201105030-00002.
   PubMed Web of Science ®Google Scholar
• Sorkness CA, Wildfire JJ, Calatroni A, Mitchell HE, Busse WW, O'Connor GT, Pongracic JA, Ross K, Gill MA, Kattan M, et al. Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents. J Allergy Clin Immunol Pract. 2013;1(2):163–171. doi:10.1016/j.jaip.2013.01.011.
   PubMed Web of Science ®Google Scholar
• Riccio AM, Mauri P, De Ferrari L, Rossi R, Di Silvestre D, Benazzi L, Chiappori A, Dal Negro RW, Micheletto C, Canonica GW. Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36 months. Clin Transl Allergy. 2017;7(1):6. doi:10.1186/s13601-017-0143-1.
   PubMedGoogle Scholar
• Loftheim H, Midtvedt K, Hartmann A, Reisæter AV, Falck P, Holdaas H, Jenssen T, Reubsaet L, Asberg A. Urinary proteomic shotgun approach for identification of potential acute rejection biomarkers in renal transplant recipients. Transplant Res. 2012;1(1):9. doi:10.1186/2047-1440-1-9.
   PubMedGoogle Scholar
• Mauri P, Riccio AM, Rossi R, Di Silvestre D, Benazzi L, De Ferrari L, Dal Negro RW, Holgate ST, Canonica GW. Proteomics of bronchial biopsies: galectin-3 as a predictive biomarker of airway remodelling modulation in omalizumab-treated severe asthma patients. Immunol Lett. 2014;162(1 Pt A):2–10. doi:10.1016/j.imlet.2014.08.010.
   PubMed Web of Science ®Google Scholar
• Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, Hargreave FE, O'Byrne PM. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009;360(10):985–993. doi:10.1056/NEJMoa0805435.
   PubMed Web of Science ®Google Scholar
• Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360(10):973–984. doi:10.1056/NEJMoa0808991.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Yancey SW, Mayer B, Gunsoy NB, Keene ON, Bleecker ER, Brightling CE, Pavord ID. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016;4(7):549–556. doi:10.1016/S2213-2600(16)30031-5.
   PubMed Web of Science ®Google Scholar
• Laviolette M, Gossage DL, Gauvreau G, Leigh R, Olivenstein R, Katial R, Busse WW, Wenzel S, Wu Y, Datta V, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol. 2013;132(5):1086–1096.e5. doi:10.1016/j.jaci.2013.05.020.
   PubMed Web of Science ®Google Scholar
• Hearn AP, Kavanagh J, d‘Ancona G, Roxas C, Green L, Thomson L, Fernandes M, Kent BD, Dhariwal J, Nanzer AM, et al. The relationship between Feno and effectiveness of mepolizumab and benralizumab in severe eosinophilic asthma. J Allergy Clin Immunol Pract. 2021;9(5):2093–2096.e1. doi:10.1016/j.jaip.2021.01.008.
   PubMed Web of Science ®Google Scholar
• Shrimanker R, Keene O, Hynes G, Wenzel S, Yancey S, Pavord ID. Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide, and their combination in severe asthma: a post hoc analysis. Am J Respir Crit Care Med. 2019;200(10):1308–1312. doi:10.1164/rccm.201903-0599LE.
   PubMed Web of Science ®Google Scholar
• Agache I, Akdis CA, Akdis M, Canonica GW, Casale T, Chivato T, Corren J, Chu DK, Del Giacco S, Eiwegger T, et al. EAACI biologicals guidelines-recommendations for severe asthma. Allergy. 2021;76(1):14–44. doi:10.1111/all.14425.
   PubMed Web of Science ®Google Scholar
• Reddel HK, Bacharier LB, Bateman ED, Brightling CE, Brusselle GG, Buhl R, Cruz AA, Duijts L, Drazen JM, FitzGerald JM, et al. Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes. Eur Respir J. 2022;59(1):2102730. doi:10.1183/13993003.02730-2021.
   PubMed Web of Science ®Google Scholar
• Holguin F, Cardet JC, Chung KF, Diver S, Ferreira DS, Fitzpatrick A, Gaga M, Kellermeyer L, Khurana S, Knight S, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2020;55(1):1900588. doi:10.1183/13993003.00588-2019.
   PubMed Web of Science ®Google Scholar
• Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, Gevaert P, Hellings P, Jiao L, Wang L, Evans RR, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA. 2016;315(5):469–479. doi:10.1001/jama.2015.19330.
   PubMed Web of Science ®Google Scholar
• Thaçi D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K, Soong W, Worm M, Szepietowski JC, Sofen H, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2016;387(10013):40–52. doi:10.1016/S0140-6736(15)00388-8.
   PubMed Web of Science ®Google Scholar
• Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–2496. doi:10.1056/NEJMoa1804092.
   PubMed Web of Science ®Google Scholar
• Bacharier LB, Jackson DJ. Biologics in the treatment of asthma in children and adolescents. J Allergy Clin Immunol. 2023;151(3):581–589. doi:10.1016/j.jaci.2023.01.002.
   PubMed Web of Science ®Google Scholar
• Wenzel S, Pavord I, Zhang B, Maroni J, Rowe P, Hamilton J, Swanson B, Amin N, Pirozzi G, Graham N. Type 2 biomarkers associated with dupilumab efficacy in patients with uncontrolled, moderate-to-severe asthma enrolled in the phase 3 study LIBERTY ASTHMA QUEST. In C101. Asthma clinical and mechanistic studies. 2018. Philadelphia, PA: American Thoracic Society.
   Google Scholar
• Corren J, Pham TH, Garcia Gil E, Sałapa K, Ren P, Parnes JR, Colice G, Griffiths JM. Baseline type 2 biomarker levels and response to tezepelumab in severe asthma. Allergy. 2022;77(6):1786–1796. doi:10.1111/all.15197.
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Wechsler ME, Brightling CE, Griffiths JM, Hellqvist Å, Bowen K, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800–1809. doi:10.1056/NEJMoa2034975.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest. 2008;118(11):3546–3556. doi:10.1172/JCI36130.
   PubMed Web of Science ®Google Scholar
• Holgate ST, Polosa R. Treatment strategies for allergy and asthma. Nat Rev Immunol. 2008;8(3):218–230. doi:10.1038/nri2262.
   PubMed Web of Science ®Google Scholar
• Oh CK, Geba GP, Molfino N. Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma. Eur Respir Rev. 2010;19(115):46–54.
   PubMedGoogle Scholar
• Walsh GM. Emerging drugs for asthma. Expert Opin Emerg Drugs. 2008;13(4):643–653. doi:10.1517/14728210802591378.
   PubMed Web of Science ®Google Scholar
• Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, Harris JM, Scheerens H, Wu LC, Su Z, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011;365(12):1088–1098. doi:10.1056/NEJMoa1106469.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Noonan M, Corren J, Korenblat P, Zheng Y, Fischer SK, Cheu M, Putnam WS, Murray E, Scheerens H, et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax. 2015;70(8):748–756. doi:10.1136/thoraxjnl-2014-206719.
   PubMed Web of Science ®Google Scholar